EXEL

Exelixis, Inc. 10-Q Filing Summary

Business Context and Reporting Period

Company: Exelixis, Inc., a genomics-based biotechnology company focused on pharmaceutical product development and comparative genomics.
Reporting Period: Quarterly report for the period ended September 30, 2001 (filed November 14, 2001).
Operations: The company operates through internal cancer discovery programs and strategic collaborations with major pharmaceutical and agricultural companies (e.g., Bristol-Myers Squibb, Protein Design Labs, Bayer, Aventis). Significant activity in the period included the acquisition of Artemis Pharmaceuticals GmbH and new collaboration agreements.

Key Financial Metrics (Nine Months Ended Sept 30, 2001)

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 59.5% year-over-year (from $17.7M to $28.2M for the nine-month period), driven by new collaborations with Bristol-Myers Squibb and Protein Design Labs, and the acquisition of Artemis.
• Expense Increase: Operating expenses rose significantly to $84.8M (from $48.8M in 2000). This includes a $6.7M charge for acquired in-process research and development (IPR&D) related to the Artemis acquisition and $3.7M in amortization of goodwill/intangibles.
• Net Loss Expansion: Net loss widened to $52.9M (from $27.3M in 2000) due to increased R&D spending, amortization, and the IPR&D charge, despite higher revenues.
• Debt and Financing: The company issued a $30.0M convertible promissory note to Protein Design Labs and raised approximately $20.0M via a private placement of common stock to Bristol-Myers Squibb.

Guidance, Outlook, and Risks

Outlook: Management expects to incur additional operating losses for the foreseeable future as it expands R&D and assumes responsibility for manufacturing and clinical development. Current cash and committed funding are projected to satisfy needs for at least the next two years.

Key Developments:

• Artemis Acquisition: Acquired majority stake in May 2001 for ~$22.3M; recorded $6.7M IPR&D expense.
• Bristol-Myers Squibb (BMS): Entered collaboration including a $5.0M upfront license fee, $3.0M/year research funding, and acquisition of rights to a Rebeccamycin analogue (cancer drug in Phase I/II).
• Pharmacia Reacquisition: Reacquired rights to metabolism and Alzheimer's programs effective Feb 2002, accelerating revenue recognition by ~$1.0M but forfeiting ~$9.0M in future annual funding.

Risks and Contingencies:

• Profitability: History of net losses; no assurance of achieving profitability.
• Capital Needs: May require additional financing; future equity sales could be dilutive.
• Collaboration Dependence: Substantially all revenues derived from collaborations; failure to meet milestones or renew agreements could severely impact revenue.
• Regulatory & Clinical Risk: Limited experience in clinical development and manufacturing; Rebeccamycin development faces significant uncertainty.
• Market Risk: Exposure to foreign currency fluctuations (German subsidiary) and interest rate changes.

Investor Verification Checklist

• Liquidity Runway: Verify the sufficiency of the $132.3M cash/investment balance against projected burn rates, especially given the new Rebeccamycin development costs.
• Collaboration Milestones: Monitor progress on BMS and Protein Design Labs agreements to ensure continued revenue streams and milestone payments.
• Rebeccamycin Development: Assess the timeline and regulatory hurdles for the acquired cancer compound, as Exelixis lacks prior manufacturing/clinical experience.
• Pharmacia Transition: Confirm the impact of losing $9.0M in annual Pharmacia funding and the success of replacing it with new collaborations.
• Stock Dilution: Review the terms of the $30M convertible note and potential future equity issuances under the S-3 registration statement.